Elicio Therapeutics (ELTX) Other Non Operating Income (2020 - 2026)

Elicio Therapeutics (ELTX) has 6 years of Other Non Operating Income data on file, last reported at $13000.0 in Q1 2026.

• Quarterly Other Non Operating Income changed N/A year-over-year to $13000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13000.0 (up 750.0% YoY) and the FY2024 annual result came in at $151000.0, down 64.8% from the prior year.
• Other Non Operating Income advanced to $13000.0 in Q1 2026, from $8000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $604000.0 in Q2 2023 to a low of -$111000.0 in Q4 2022.
• A 4-year average of $120900.0 and a median of $10500.0 in 2024 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2022 — Other Non Operating Income sank 109.38% — and 2023, when it surged 527.03%.
• Tracing ELTX's Other Non Operating Income over 4 years: stood at -$111000.0 in 2022, then surged by 527.03% to $474000.0 in 2023, then plunged by 98.31% to $8000.0 in 2024, then jumped by 62.5% to $13000.0 in 2026.
• The last three Other Non Operating Income figures came in at $13000.0 (Q1 2026), $8000.0 (Q4 2024), and -$1000.0 (Q3 2024), per Business Quant data.